WISeKey to Present at Maxim Tech Conference Discover the Innovations Reshaping Tomorrow on June 3 at 8:30am ET
June 02, 2025 01:00 ET | Source: Wisekey International Holding Ltd. WISeKey…
Vodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and services
Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive…
Best SEO Tool (June 2025): Moz Named Top SEO Software by Software Experts
NEW YORK CITY, June 01, 2025 (GLOBE NEWSWIRE) -- Software Experts has…
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In…
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the…
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a…
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or…